Goldman Sachs Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $74
Goldman Sachs analyst Matt Dellatorre initiates coverage on Zoetis (NYSE:ZTS) with a Neutral rating and announces Price Target of $74.
Stocks · News reference
Zoetis Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Zoetis (NYSE:ZTS) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Zoetis Inc. (ZTS)
Filed: 2026-10-13 AccNo: 0001555280-26-000044 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Is it the Right Time to Add Phibro Stock to Your Portfolio?
Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.
Zoetis Says 25% Of Simparica Trio-Treated Dogs Had Adult Heartworms vs. 75% On NexGard Plus In Drug-Resistant Heartworm Study